Tag Archives: HEA

Guardant Health to integrate Lunit’s AI-based scoring algorithm for PD-L1 into its portfolio to enhance cancer biomarker detection


  • Powered by Lunit SCOPE PD-L1, the Guardant360 TissueNext PD-L1 test with Guardant Galaxy™ shows improved detection of the biomarker in NSCLC
  • Lunit’s AI solution is the first application in Guardant Galaxy, a suite of AI and other technology tools that enhance Guardant Health’s portfolio of cancer tests

SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ — Lunit (KRX:328130.KQ), in partnership with leading precision oncology company Guardant Health, today announced the integration of its AI-based PD-L1 scoring algorithm into Guardant’s testing workflow to enhance biomarker detection in the Guardant360 TissueNextTM PD-L1 test for non-small cell lung cancer (NSCLC).

The newly integrated algorithm will enable Guardant to offer augmented biomarker assessment for NSCLC patients through AI-based quantification of tissue samples using a scoring system generated by Lunit SCOPE PD-L1. The enhanced Guardant test is designed to support pathologists in diagnosing PD-L1 status with higher accuracy and efficiency. Through the AI software, the test showed improved detection of PD-L1 by more than 20 percent compared to manual pathologist interpretation in the most challenging cases in NSCLC1.

Lunit SCOPE PD-L1 is a CE-marked AI solution for detecting and analyzing PD-L1, a cancer biomarker. The solution may assist pathologists by minimizing interpretation discrepancy and allowing better prediction of treatment outcomes for non-small cell lung cancer (NSCLC) patients, as demonstrated in study findings published in the European Journal of Cancer.

Lunit SCOPE PD-L1’s integration with the Guardant360 TissueNext PD-L1 test is the first application in Guardant Galaxy, Guardant Health’s suite of technology applications developed internally and through outside partnerships to enhance the performance and utility of its portfolio of cancer tests.

The two companies have been in partnership since 2021, following a strategic investment from Guardant Health to Lunit.

“We are honored to partner with Guardant Health in leveraging the power of AI and digital pathology to enhance the capabilities of their comprehensive genomic profiling tests for cancer patients,” said Brandon Suh, CEO of Lunit. “The development of the AI-supported scoring algorithm for the Guardant360 TissueNext PD-L1 test is a great example of using advanced medical image analytics to enhance precision diagnostics in lung cancer and help doctors find the right treatment for the right patients.”

“With Guardant Galaxy, we are now accessing the most advanced AI techniques and the latest complementary technologies from leading companies in cancer diagnostics to enhance the capabilities of our tests and provide oncologists and researchers with precise and actionable information,” said Helmy Eltoukhy, co-CEO of Guardant Health. “The digital pathology solution from Lunit has already demonstrated the power of AI to help improve detection of PD-L1 in certain cases of non-small cell lung cancer. We believe it has the potential to contribute much more broadly to advances in identifying cancer biomarkers and informing treatment decisions.”

About Lunit

With AI, Lunit aims to ‘conquer cancer,’ one of the leading causes of death worldwide. Lunit is an AI software company devoted to developing AI solutions for precision diagnostics and therapeutics, to find the right diagnosis at the right cost, and the right treatment for the right patients. Lunit, a portmanteau of ‘learning unit,’ is a deep learning-based medical AI company devoted to developing advanced medical image analytics and data-driven imaging biomarkers via cutting-edge technology.

Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. Its technology has been recognized at international AI competitions surpassing top companies like Google, IBM, and Microsoft. As a medical AI company with a focus on clinical evidence, the company’s findings are presented in major peer-reviewed journals such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences including ASCO and AACR. After receiving FDA clearance and the CE Mark, Lunit INSIGHT CXR and MMG are clinically used in approximately 1,000 hospitals and medical institutions across more than 40 countries. Lunit is headquartered in Seoul, South Korea with offices and representatives around the world.

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. Lunit SCOPE PD-L1 is CE marked in Europe and has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantNFINITY® tests for advanced stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the ShieldTM test, aims to address the needs of individuals eligible for cancer screening.

References

1. Sangjoon Choi et al. Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response, European Journal of Cancer 2022, Volume 170, 17-26

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/guardant-health-to-integrate-lunits-ai-based-scoring-algorithm-for-pd-l1-into-its-portfolio-to-enhance-cancer-biomarker-detection-301734438.html

Correction – Health in Transportation Releases New Smartphone Face-Scanning Application Aimed at Uncovering Potentially Serious Health Concerns in Professional Drivers

Correction Notice

Please note the following corrections to the Press Release issued Jan 17, 2023:

  • The CDL Health Scanner is a product of Health in Transportation. NuraLogix does not hold any liability for any applications distributed under the Health in Transportation name.
  • NuraLogix technology, service and products do not uncover, nor identify life-threatening health conditions. NuraLogix technology, service and products are intended to improve your awareness of general wellness and health.
  • Note that NuraLogix technology, service and products are For Investigational Use Only within the USA. NuraLogix technology, service and products are not a substitute for the clinical judgment of a health care professional. NuraLogix technology, service and products are not intended to diagnose, treat, mitigate or prevent any disease, symptom, disorder or abnormal physical state. Always consult with a health care professional or emergency services if you believe you may have a medical issue.
  • NuraLogix is not responsible for any third-party products that may integrate NuraLogix technology, service or products. NuraLogix does not make any claims about, nor have they evaluated the claims of any third-party products using NuraLogix technology, service or products.
  • NuraLogix technology, service and products do not predict the risk of, nor do they provide Obstructive Sleep Apnea (OSA) measurements in any way. NuraLogix technology, service and products do not provide customized health coaching from Medwell, nor sleep-apnea solutions by Dedicated Sleep. NuraLogix technology, service and products do not provide health education, or resources to assist with lifestyle changes.

Corrected Press Release

Please note the following corrected press release. A previous release sent on January 17 contained incorrect or outdated information.

ST. GEORGE, Utah, Jan. 26, 2023 /PRNewswire/ — Health in Transportation, a health and wellness solution provider for the transportation industry, released a revolutionary preventative health tool for drivers called CDL Health Scanner.

Accessed through a specific URL on a smartphone, CDL Health Scanner’s proprietary technology uses a smartphone camera to scan an individual’s face and analyze key vital signs. This unique, driver-centric system uses revolutionary technology from NuraLogix, called Transdermal Optical Imaging (TOI)™, in which a conventional video camera is used to extract blood flow information from the face. Risk factors for hypertension, type-2 diabetes and more are revealed to the individual user on an easy-to-interpret results page.

“It’s an exciting day for the transportation industry,” said Bob Perry, president of Health in Transportation. “For less than the cost of a couple coffee drinks, this new smartphone app will provide health information to drivers, potentially salvaging thousands of driving careers. Our partnership with NuraLogix is dedicated to bringing innovative solutions to directly impact the driver shortage and help keep America’s professional drivers on the road instead of being sidelined due to bad health.”

This new, confidential CDL Health Scanner was developed specifically to protect drivers. With the transportation industry experiencing a shortage of close to 80,000 drivers each year– along with the fact that putting a new driver behind the wheel often involves a five-figure expense for the carrier–thousands of skilled drivers are disqualified from driving each month due to poor health outcomes.

CDL Health Scanner not only alerts drivers of potentially serious health concerns, but it also provides health education focused on the driver and guides them toward resources that can assist with lifestyle changes. Often, drivers are completely unaware of some of these underlying medical conditions, and CDL Health Scanner aims to bring awareness to these important metrics. The app provides support for drivers who may be at risk by providing them with the nearest location of one of the six thousand Higi health check stations.

CDL Health Scanner can be purchased by visiting www.cdlhealthscanner.com.

About Health in Transportation
Health in Transportation (HIT) provides innovative and practical health and wellness solutions for professional drivers in trucking and mass transit. For almost forty years, their programs have helped thousands of drivers avoid medical disqualification with unique coaching mechanisms that drivers can utilize even while they are on the road. Known as ‘The Trucker Trainer’ by professional drivers nationwide, Bob Perry, president of HIT, brings a very distinctive perspective to the issue of a driver’s health and life expectancy. He comes from a family of professional drivers and has spent decades working on driver health initiatives.

About NuraLogix
NuraLogix are the Toronto-based pioneers of the world’s first contactless blood pressure and vital sign measurement solution. NuraLogix uses its patented Transdermal Optical Imaging (TOI™) technology in which a conventional video camera is used to extract facial blood flow information. This technology is the evolution of extensive peer-reviewed research and clinical studies, differentiating NuraLogix from their competitors. NuraLogix has conducted multiple clinical studies and published several research papers in notable scientific publications such as Frontiers in Psychology, Scientific Reports, and the Journal of Natural Sciences (JNS). To date the company has been issued 13 US patents with additional patents pending. Visit their website at www.nuralogix.ai.

For inquiries related to Anura™ and NuraLogix technology, service and products please contact Chris Lin, Chief Marketing Officer, ChrisLin@nuralogix.ai; For inquiries related to CDL Health Scanner and products and services provided by Health in Transportation, please contact Bob Perry, President of Health in Transportation,  bob@healthintransportation.com

Ecolog International Appoints Juan Chaparro as Executive Director and Chairman of the Board

DUBAI, UAE, Jan. 9, 2023 /PRNewswire/ — Ecolog International, a leading global provider of integrated services and logistics solutions for life support, supply chain, energy and healthcare industries, announced the appointment of Juan Chaparro as Executive Chairman of the Board, as of 01 January 2023.

With over 30 years’ experience as an executive in supply chain management, procurement and sourcing, having worked for globally recognized companies such as Zara (Inditex), Esprit and Primark, Mr. Chaparro brings a wealth of expertise in complex logistics management in fast-paced environments as well as the B2C focus. This aligns with Ecolog’s vision and growth strategy and makes him a valuable addition to the leadership team.

Commenting on his new role, Juan Chaparro said, “Ecolog is a unique organization with distinguished history and the potential to help improve all aspects of the lives of the people it serves, from water and sanitation to catering, healthcare and the wider environment. Its people-driven focus and family-like culture, both internally and externally, are among the many reasons I am excited to be joining”

Mr. Chaparro’s appointment comes at a pivotal time as Ecolog progresses with expanding its service offering into customized healthcare solutions, clean water and renewable energy as well as sustainable food technologies. With projects in both emerging and established markets catering to various institutional clients, Ecolog is set to leverage its scale and footprint to also provide direct services to consumers.

“This is an exciting phase of the company’s development, investigating how we can mobilize our most valuable asset – our people and their skills – to grow their abilities and expand our capacity to assist more people in more ways. I am eager to contribute in my new role and honoured to lead our incredible team towards new heights of success”, said Juan Chaparro.

About Ecolog

Ecolog International is a global provider of integrated services and sustainable solutions tailored to the needs of diverse range of customers in the humanitarian, healthcare, energy, mining and infrastructure industries. Incorporated over two decades ago in Germany, with the footprint in nearly 40 countries, the company’s service portfolio includes life support, supply chain management, construction, engineering, healthcare and environmental services. Driven by the passion to serve people and communities, Ecolog has an extensive experience in providing fast response solutions, integrated and complex logistics as well as mission-critical operations.

Press Contact: press@ecolog-international.com T: +971 (0)4 299 4500 

Waterdrop and Jemincare Collaborate on the “Digital Service Platform for CKD Patients”

BEIJING, Jan. 4, 2023 /PRNewswire/ — Waterdrop and Jemincare recently reached a cooperation, according to which both sides will jointly launch the “Digital Service Platform for CKD Patients”. Featuring both online and offline service modules ranging from follow-up visits and consultation with doctors to interpretation of data reports and popularization of disease knowledge, the platform is expected to offer patients efficient, convenient, and integrated chronic disease management services, and enhance their experience even without visiting hospitals.

Jemincare is committed to delivering CKD patients with a better experience in drug use, diagnosis, and treatment by offering services outside hospitals throughout the course of the disease. Boasting a series of proven tools devised to improve patient management services, Waterdrop Patient Platform, built on a patient-centric approach, can provide patients with services in the whole disease course outside hospitals. The bilateral cooperation is of positive significance in helping CKD patients solve problems associated with diagnosis, drug use, and daily care during the long cycle of treatment.

According to Yao Hu, co-founder of Waterdrop and General Manager of Waterdrop’s Pharmaceutical Innovation Business Unit, Waterdrop Patient Platform enjoys a solid foundation in offering patient services across the whole disease course outside hospitals and has put in place a multi-dimensional operation system that provides patients with one-on-one Q&A services related to reporting interpretation, drug use, disease knowledge explanation, nutrition & lifestyle guidance, and psychological support. As of September 2022, the platform had served 3 million patients with severe diseases and set up nearly 1,600 communities that covered patients of 12 common serious diseases and rare diseases. “Centering on patient needs, Waterdrop Patient Platform will further optimize service processes to bring more comprehensive, professional, and considerate services to patients. Also, empowered by digital technologies, the platform can help pharmaceutical partners boost quality and efficiency.”

About Waterdrop Inc.

Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about Waterdrop’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in Waterdrop’s filings with the SEC. All information provided in this press release is as of the date of this press release, and Waterdrop does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Cision View original content:https://www.prnewswire.com/news-releases/waterdrop-and-jemincare-collaborate-on-the-digital-service-platform-for-ckd-patients-301713005.html

Source: Waterdrop Inc.

Complete Genomics to Present its Multiple, Innovative Sequencing Platforms at BIOTECH SHOWCASE™ 2023

Enhanced sequencing capabilities offer opportunity to accelerate breakthroughs in life science research

SAN JOSE, Calif., Dec. 30, 2022 /PRNewswire/ — Complete Genomics Inc(https://completegenomics.mgiamericas.com/), a subsidiary of MGI Tech Co., Ltd., today announced that it is presenting at Biotech Showcase™ 2023, taking place in San Francisco at the same time as the JP Morgan healthcare conference. Registered attendees can view Complete Genomics presentation live and through 24×7 on-demand access if scheduling does not allow viewing during the main event week.

Complete Genomics offers complete high throughput sequencing instrumentation and related products, including sample extraction, library prep, automation system, sequencing platforms, and bioinformatics. Rade Drmanac, PhD, Chief Scientific Officer, will provide an overview of the complete suite of high throughput sequencing instruments and related products. The live presentation will be on:

Date: Monday, January 9
Time: 16:30pm PST
Venue: Hilton San Francisco Union Square Hotel
Room: Franciscan D

“Dating back to as early as 2006, we have been at the forefront of life science innovation and continue to redefine sequencing possibilities through our innovative DNBSEQTM technology,” said Dr. Drmanac. “Over the years, our massively parallel sequencing (MPS) and sample processing automation products have empowered countless customers and partners around the world in their scientific research and clinical applications. As we aim to broaden our reach into the US market, we look forward to attending Biotech Showcase™ to demonstrate our enhanced sequencing capabilities and how we can help our partners accelerate breakthroughs in life science and healthcare with this state-of-the-art technology.”

Complete Genomics sequencing platforms are based on DNBSEQTM, sample extraction, library prep, automation system, and bioinformatics to the US market and beyond. In August 2022, its DNBSEQ-G400C* sequencer was released in the US with immediate adoption in several customer labs and partnerships with various life science companies.

Moreover, Complete Genomics will launch at Biotech Showcase the “Empowerment Program America”, which will bring choice to sequencing by collaborating with researchers to develop grant proposals.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

“We are delighted that Complete Genomics will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

ABOUT BIOTECH SHOWCASE

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

ABOUT COMPLETE GENOMICS

Complete Genomics, a subsidiary of MGI Tech Co., Ltd., is a global life science company offering lab automation and a comprehensive high throughput sequencing product portfolio. Founded in 2006 and currently located in San Jose, California, Complete Genomics maintains a demo lab and full supply center with all of its sequencers and lab automation equipment on display. Complete Genomics released its first next-generation sequencing system, the DNBSEQ-G400C* platform in the US, in August 2022. For all sequencer specifications, please visit the Complete Genomics website.

Follow Complete Genomics on Twitter at @ Complete Genomics and Biotech Showcase at @EBDGroup and @Demy_Colton and tag your posts with #BiotechShowcase

*Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, Spain, UK, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, Austria, and Romania. Unless otherwise informed, StandardMPS sequencing reagents, and sequencers for use with such reagents are not available in Hong Kong. No purchase orders for StandardMPS products will be accepted in the USA until after January 1, 2023.

Cision View original content:https://www.prnewswire.com/news-releases/complete-genomics-to-present-its-multiple-innovative-sequencing-platforms-at-biotech-showcase-2023-301711121.html

CGTN: Vitality under COVID-19: China’s smart ports aid increased throughput

BEIJING, Dec. 29, 2022 /PRNewswire/ — China’s Qingdao Port, a subsidiary of Shandong Port Group and the second-largest foreign trade port in east China’s Shandong Province, has seen an increase in anchorage rotations of very large container ships, according to China Media Group.

The port has handled ultra-large container ships more than 300 times. Ultra-large container ships are usually 400 meters long and have a capacity of over 20,000 twenty-foot equivalent units (TEU).

The port has also handled 200-meter-long container ships more than 3,900 times, a 7-percent increase year on year, CMG said.

Handling that much freight under the impact of COVID-19 is challenging, particularly with reduced labor. However, the unloading rate at the Qingdao Port increased by 16 percent from January to November, thanks to the port’s record-setting intelligent system.

The COVID-19 pandemic has greatly impacted the global port and water transportation industry. However, China’s major ports have seen an increase in throughput and made significant progress in digital and intelligent construction, thereby playing a leading role in the intelligent development of ports globally.

Qingdao Port is the world’s first to have an air-track intelligent transporting system capable of handling 1.5 million TEUs annually. The system set a new world record in June for managing as many as 67.76 TEUs in an hour, with an average of 60.18 TEUs per hour, a 14.2-percent jump from its previous record.

China now leads the world in the number of automated terminals, both built and under construction, according to the Ministry of Transport. All the major ports in Shanghai and Tianjin are equipped with automated bridge cranes or tracks.

Coupled with the continuous investment in domestic ports and a large number of high-tech enterprises, the concept and practice of smart port construction have been innovative, Mi Weijian, a professor at Shanghai Maritime University, told Xinhua.

For large corporate ports, such as the Shandong Port Science and Technology Group, in-house cooperation is the key to upgrading existing facilities into a fully automated waterfront container terminal, which helps reduce the overall costs by 70 percent compared with newly built terminals, according to Xinhua.

“Now we have traditional terminals, semi-automatic terminals and fully automatic terminals,” said Wang Yusheng, deputy general manager of the group. “The loading and unloading of a ship can be done in three different kinds of terminals, which maximizes the integration of terminal resources.

Link: https://news.cgtn.com/news/2022-12-28/Vitality-under-COVID-19-China-s-smart-ports-aid-increased-throughput-1g7OLnTDJtK/index.html

CGTN: Vitality under COVID-19: China gears up for medical supplies

BEIJING, Dec. 28, 2022 /PRNewswire/ — China has made efforts to ensure the medical supplies needed for COVID-19 prevention and control after it loosened its epidemic measures in early December, which was followed by an increase in infections and surging demand for medicines.

The country’s National Medical Products Administration has urged medical regulatory authorities at all levels to adopt various enhanced measures, such as sending personnel to factories for inspections and strengthening quality sampling inspections, to safeguard medical supplies needed, such as therapeutic medicines, testing reagents, vaccines, medical masks and protective suits.

Pharmaceutical enterprises have also striven to secure supply.

East China’s Shandong Province is the largest production base of raw materials for antipyretic analgesic medicines in the country. Many companies in the province focus on export markets, but quickly adjusted their distribution channels and increased production capacity in order to secure domestic supplies.

Local government departments have also helped companies to access to raw materials and transportation to ensure the stability of the industrial supply chain for key products. Raw materials and preparations have been produced at full capacity, Zhang Haibo, director at the Department of Industry and Information Technology in Shandong Province, told China Media Group.

Zhang said that they would also coordinate between production enterprises, medical institutions and commercial circulation among others, and organize the delivery of medicines to improve the accessibility to medicines for the people.

Pharmaceutical companies across the country have also adopted measures, such as technological transformations and new production lines, to expand production capacity and meet market demand.

Tan Guanghua, general manager at Pharmaceutical Business Department of Guangzhou Xiangxue Pharmaceutical Co., LTD. in south China’s Guangdong Province, said that they have opened two new production lines to produce Chinese patent medicines and increase daily production capacity by about 50 percent.

For antigen detection reagents, Zhou Jian, deputy general of the consumer product industry department at the Ministry of Industry and Information Technology, said at a press conference on December 14 that all 42 manufacturers have been included in a government white list and were required to procure and store key materials to ensure sufficient supply of the reagents.

Zhou said the country’s vaccine could also meet the needs of the current epidemic prevention and control, since China has built the world’s largest production line of COVID-19 vaccine, with an annual capacity of more than 7 billion doses and an output of over 5.5 billion doses. 

In response to the rising demand for N95 masks, the country has improved its production, according to Zhou.

Medical services provided by hospitals and clinics

Multiple makeshift fever clinics have been set up at the grassroots level in cities in east China’s Jiangsu and Zhejiang provinces, central Henan Province and southern Guangdong Province to provide timely treatment for people with COVID-19 symptoms.

Doctors in the makeshift clinics would diagnose patients and prescribe drugs, making it convenient for locals in urgent need of medical services.

In southwest China’s Guizhou Province, some community clinics have opened online consulting services which support medicine prescription and delivery. Some medical institutions have set up special treatment channels for vulnerable groups of people such as the elderly, the pregnant and infants.

Shanghai has expanded the capacity of fever clinics in community health service centers, branch centers and village clinics to receive the increasing numbers of patients.

China has a three-tier system to grade hospitals, with primary, secondary and tertiary hospitals. Primary and secondary hospitals usually receive patients from certain communities and districts. In Shanghai, these two levels of hospitals so far have responded to 60 percent of the whole treatment requirements.

Tertiary hospitals have the largest number of beds and provide comprehensive medical services and are at the top of the list. Many tertiary hospitals in Shanghai have enlarged their ICU capacity and increased their medicine inventories.

Beijing Municipality urged its tertiary hospitals to play a role in medical treatment, give full play to expert teams, and provide specific treatment for critically ill patients who are affected by the novel coronavirus in accordance with their cases, and make every effort to raise the cure rate and reduce the mortality rate, according to a spokesperson at a press conference held in Beijing on Saturday.

https://news.cgtn.com/news/2022-12-25/Vitality-under-COVID-19-China-gears-up-for-medical-supplies-1g2XIXZjmGA/index.html

CGTN: Infrastructure, vaccines and space: China-Arab sci-tech cooperation

BEIJING, Dec. 12, 2022 /PRNewswire/ — Under the Belt and Road Initiative (BRI), China-Arab cooperation in the fields of infrastructure, space and health has been continuously developed in a sustainable manner.

China has vowed to accelerate the development of the China-Arab inter-governmental science and technology innovation cooperation mechanism.

The country will implement more partner projects, and continue to improve the sci-tech capabilities of Arab states.

Lusail Stadium: first China-built World Cup venue

Lusail Stadium, the main venue for this year’s World Cup, was constructed with China Railway Construction Corporation as the main contractor.

Shaped like a date palm bowl or an enamel lantern, the stadium will host the World Cup final, scheduled for December 18.

It is the first time a Chinese company has built a World Cup venue, which is featured on the new 10-riyal banknote of Qatar.

“The Lusail Stadium is by far the world’s largest, most advanced and most complex professional football stadium built to FIFA standards,” Li Chongyang, head of the Chinese side of the engineering team, told the China Media Group (CMG).

Lusail Stadium, which can host 80,000 spectators, shows Chinese enterprises’ technical capabilities and service levels, Hassan Al Thawadi, secretary general of the Supreme Committee for Delivery and Legacy for 2022 FIFA World Cup, told CGTN.

China-UAE joint vaccines projects

The United Arab Emirates (UAE) helped China with the clinical trial of its COVID-19 vaccine and later established localized production lines.

In 2020, the UAE approved registration of an inactivated vaccine developed by China’s Sinopharm.

“The UAE was the first country to approach a Chinese vaccine,” Ali Obaid Al Dhaheri, the UAE ambassador to China, told CGTN. “The production facility can produce 200 million doses per year. The vaccine is not for the UAE, not for China, but for the rest of the world.”

Space cooperation

China is pushing forward space cooperation with countries participating in the BRI.

China and Saudi Arabia signed a memorandum of understanding on March 16, 2017, sharing the scientific data in space cooperation.

The two then jointly unveiled three lunar images acquired through cooperation on the relay satellite mission for Chang’e-4 lunar probe, according to the China National Space Administration.

In 2018, the China-Arab States BDS/GNSS Center, the first overseas center for China’s indigenous Beidou Navigation Satellite System (BDS), was inaugurated in Tunisia. BDS-related cooperation expanded to more Arab states in 2021 as they agreed to implement more pilot projects.

In addition, Kuwait’s national satellite team looks forward to cooperating with China.

Link: https://news.cgtn.com/news/2022-12-10/Infrastructure-vaccines-and-space-China-Arab-sci-tech-cooperation-1fDKJNs4QuI/index.html

Waterdrop Inc. to Report Third Quarter 2022 Financial Results on December 6, 2022

BEIJING, Dec. 2, 2022 /PRNewswire/ — Waterdrop Inc. (NYSE: WDH) (“Waterdrop” or the “Company”), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2022, before U.S. markets open on Tuesday, December 6, 2022.

Waterdrop’s management team will hold a conference call on December 6, 2022 at 7:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows:

International:

1-412-317-6061

United States Toll Free:

1-888-317-6003

Hong Kong Toll Free:

800-963976

Hong Kong:

852-58081995

Mainland China:

4001-206115

Elite Entry Number:

5857670

Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.

A telephone replay will be accessible two hours after the conclusion of the conference call through December 13, 2022 by dialing the following numbers:

United States Toll Free:

1-877-344-7529

International:

1-412-317-0088

Access Code:

4470089

Additionally, a live and archived webcast of the conference call will be available at the Company’s investor relations website at http://ir.waterdrop-inc.com/.

About Waterdrop Inc.

Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.

For investor inquiries, please contact

Waterdrop Inc.
IR@shuidi-inc.com

Cision View original content:https://www.prnewswire.com/news-releases/waterdrop-inc-to-report-third-quarter-2022-financial-results-on-december-6-2022-301692247.html

Source: Waterdrop Inc.

Fovia Ai to Showcase AI Visualization Integrations at IAIP Exhibit, RSNA 2022

Fovia Ai Provides Efficiency Gains for Radiology Workflows

CHICAGO, Nov. 27, 2022 /PRNewswire/ — Fovia Ai, Inc., a subsidiary of Fovia, Inc., a world leader in advanced visualization for nearly two decades and a preeminent provider of zero-footprint, cloud-based imaging SDKs, today announced that it will be showcasing AI visualization, navigation and seamless integrations of AI that provide significant efficiency gains in the radiology ecosystem, in the Imaging Artificial Intelligence in Practice (IAIP) demonstration being held November 27November 30 at the 108th Scientific Assembly and Annual Meeting of the Radiology Society of North America (RSNA 2022) at McCormick Place in Chicago.

Fovia Ai utilizes XStream® aiCockpit® in collaborative exhibit showcasing AI integrations in the radiology ecosystem
Fovia Ai utilizes XStream® aiCockpit® in collaborative exhibit showcasing AI integrations in the radiology ecosystem

RSNA attendees visiting the IAIP exhibit will be able to explore AI integrations from 19 exhibitors, with 30 products, based on real-world clinical scenarios and will see live demonstrations of Fovia Ai software integrated with vendors including 3M M*Modal, Bayer, GE Healthcare, Hyperfine, Lunit, Microsoft, Nuance, Nvidia, Siemens Healthineers, Smart Reporting, Qvera, Qure.ai, Therapixel and Visage Imaging. The interactive exhibit provides attendees access to emerging AI technologies, demonstrates the interoperability standards needed to integrate into the workflow of diagnostic radiology, and highlights AI-driven products that remove barriers to clinical adoption.

“Fovia is proud to join the IAIP emphasizing interoperability. It has been enlightening to work with the other vendors to connect many disparate AI products in real-world, clinical scenarios while providing unprecedented efficiency gains with XStream® aiCockpit®. We are pleased that the existence of standards such as FHIR, FHIRcast, DICOMweb/WADO, HL7, RSNA/ACR CDE’s (including RadElements and RadLex), and SOLE allow our AI viewer technology to easily communicate and interact with the various AI vendors’ algos, AI Orchestrator Systems, Reporting Systems and PACS Archives/Viewers. This demo will show the future of interconnected AI workflows within the radiology ecosystem,” stated Fovia Ai’s Chief Technology Officer, Kevin Kreeger, Ph.D.

Adjacent to the IAIP demonstration, in the Fovia Ai booth (#4129), attendees can:

  • Explore AI-driven advanced visualization via XStream® aiCockpit® and XStream® aiPlatform®, and see how Fovia Ai technology enables radiologists and clinicians to efficiently access, interact with and modify AI results directly within their existing workflows. Preview select workflows integrated with a variety of vendors.
  • Discover how XStream® aiCockpit® provides multiple paths for integrating AI. Learn how to leverage AI capabilities for PACS, reporting systems, universal viewers and hospital systems in a variety of ways—embedded zero-footprint web app, white-label floating web browser, or comprehensive SDK Integration. Learn more.
  • Learn how to quickly develop advanced visualization applications that achieve efficiency gains by leveraging optimized segmentation tools, automated image processing and efficient reporting of clinical results. Schedule a meeting at RSNA.

To learn more about Fovia and Fovia Ai’s complete product suites or arrange a demonstration at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America, November 27 – November 30, contact us.

About Fovia Ai 

Fovia Ai, Inc. is a subsidiary of Fovia, Inc., a world leader in advanced visualization, a preeminent provider of cloud-based, zero-footprint imaging SDKs, and the developer of High Definition Volume Rendering®, XStream® HDVR®, F.A.S.T.® RapidPrint® and TruRender®. Fovia Ai’s flagship products, XStream® aiCockpit® and XStream® aiPlatform® enable radiologists and clinicians to efficiently access AI results directly within their existing workflows from any PACS, worklist, dictation software or hospital system. Complementary products in Fovia Ai’s product suite include F.A.S.T.® AI Annotation, F.A.S.T.® AI Validation, F.A.S.T.® AI Workflows, F.A.S.T.® Interactive AI and F.A.S.T.® Interactive Segmentation, collectively providing tools to annotate, validate, modify, accept/reject, interact with and segment data. The flexible architecture of Fovia Ai’s product suite and Fovia’s nearly two decades of radiology integration experience facilitate seamless integrations with a variety of partners, platforms, processors and operating systems.

For additional information and to learn more about commercial, academic or research licensing, visit fovia.ai or fovia.com.

IMPORTANT REGULATORY NOTICE: The applications mentioned herein are for investigational use only at this time.

Source: Fovia Ai, Inc.